Hormone Replacement Therapy for Use in Postmenopausal Women for Relief of Hot Flushes and Urogenital Symptoms.
A Multicenter, Double-Blind, Controlled, Randomized Study to Compare the Efficacy in Relief of Hot Flushes in Women Receiving Oral Estradiol Acetate Tablets, Oral Estradiol Tablets or Oral Conjugated Equine Estrogens
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85031
- Warner Chilcott Investigational Site
-
-
California
-
Carmichael, California, United States, 95608
- Warner Chilcott Investigational Site
-
San Diego, California, United States, 92108
- Warner Chilcott Investigational Site
-
San Diego, California, United States, 92123
- Warner Chilcott Investigational Site
-
-
Florida
-
Aventura, Florida, United States, 33180
- Warner Chilcott Investigational Site
-
Boynton Beach, Florida, United States, 33437
- Warner Chilcott Investigational Site
-
Clearwater, Florida, United States, 33765
- Warner Chilcott Investigational Site
-
Daytona Beach, Florida, United States, 32114
- Warner Chilcott Investigational Site
-
Gainesville, Florida, United States, 32605
- Warner Chilcott Investigational Site
-
Longwood, Florida, United States, 32779
- Warner Chilcott Investigational Site
-
Melbourne, Florida, United States, 32935
- Warner Chilcott Investigational Site
-
Miami, Florida, United States, 33143
- Warner Chilcott Investigational Site
-
Palm Springs, Florida, United States, 33461
- Warner Chilcott Investigational Site
-
Pinellas Park, Florida, United States, 33781
- Warner Chilcott Investigational Site
-
Sarasota, Florida, United States, 34232
- Warner Chilcott Investigational Site
-
Venice, Florida, United States, 34285
- Warner Chilcott Investigational Site
-
-
Georgia
-
Roswell, Georgia, United States, 30075
- Warner Chilcott Investigational Site
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Warner Chilcott Investigational Site
-
Peoria, Illinois, United States, 61615
- Warner Chilcott Investigational Site
-
-
Maryland
-
Laurel, Maryland, United States, 20707
- Warner Chilcott Investigational Site
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68510
- Warner Chilcott Investigational Site
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27612
- Warner Chilcott Investigational Site
-
Winston Salem, North Carolina, United States, 27103
- Warner Chilcott Investigational Site
-
-
Ohio
-
Cleveland, Ohio, United States, 44122
- Warner Chilcott Investigational Site
-
Columbus, Ohio, United States, 43212
- Warner Chilcott Investigational Site
-
Mogadore, Ohio, United States, 44260
- Warner Chilcott Investigational Site
-
-
Oregon
-
Portland, Oregon, United States, 97201
- Warner Chilcott Investigational Site
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15206
- Warner Chilcott Investigational Site
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Warner Chilcott Investigational Site
-
-
Utah
-
Salt Lake City, Utah, United States, 84124
- Warner Chilcott Investigational Site
-
-
Washington
-
Spokane, Washington, United States, 99201
- Warner Chilcott Investigational Site
-
Tacoma, Washington, United States, 98405
- Warner Chilcott Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 40 years of age; bilateral oophorectomy ≥ 35 years of age.
Non-hysterectomized women:
- Amenorrhea for ≥ 12 months or
- Amenorrhea for ≤ 12 months, but longer than 6 months, and serum FSH (follicle stimulating hormone) levels > 40 units/L and serum estradiol levels < 20 pg /mL,
Hysterectomized women:
- Bilateral oophorectomy - subjects may enter the study 6 weeks after surgery or
- History of removal of ovaries may be confirmed by - serum FSH levels > 40 units/L and serum estradiol levels < 20 pg/mL or via surgical report / ultrasound.
- Seven or more moderate or severe hot flushes daily for 1 week or 60 or more moderate or severe flushes in 1 week during the 2 week screening period prior to study entry.
Exclusion Criteria:
- Hormone therapy administered via the following routes and during the specified timeframes: oral within 8 weeks, vaginal (rings, creams, gels) within 1 week, transdermal within 4 weeks, intramuscular within 6 weeks, progestational implants, estrogen or estrogen/progestational injectable drug therapy within 3 months, estrogen pellet or progestational injectable within 6 months.
- Abnormal Pap smear suggestive of low grade squamous intraepithelial lesion (LGSIL) or worse. Enrollment of subjects with an ASCUS (atypical squamous cells of undetermined significance) interpretation must be discussed with the sponsor prior to randomization.
- Urinary tract infection
- Congestive heart failure
- Uncontrolled hypertension; sitting systolic BP ≥ 160 mmHg or diastolic ≥ 95 mmHg
- History of stroke or transient ischemic attacks
- Treatment with anticoagulants (heparin or warfarin).
- Uncontrolled thyroid disorders.
- Insulin-dependent diabetes mellitus.
- Increase frequency or severity of headaches including migraines during previous estrogen therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Estradiol acetate (E3A)
|
Tablet containing 0.9 mg E3A, daily oral administration.
|
|
Active Comparator: Estradiol
|
Tablet containing 1 mg estradiol, daily oral administration.
Other Names:
|
|
Active Comparator: Conjugated equine estrogens (CEE):
|
Tablet containing 0.625 mg CEE, daily oral administration.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean Change From Baseline in the Number of Moderate to Severe Hot Flushes, Week 4, ITT (Intention to Treat) Population
Time Frame: Baseline to Week 4
|
Severity of hot flush definitions: mild - sensation of heat without perspiration, moderate - sensation of heat with perspiration, able to continue activity, severe - sensation of heat with perspiration, causing the subject to stop activity or awaken from sleep
|
Baseline to Week 4
|
|
Mean Change From Baseline in the Number of Moderate to Severe Hot Flushes, Week 12, ITT Population
Time Frame: Baseline to Week 12
|
Severity of hot flush definitions: mild - sensation of heat without perspiration, moderate - sensation of heat with perspiration, able to continue activity, severe - sensation of heat with perspiration, causing the subject to stop activity or awaken from sleep
|
Baseline to Week 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean Change From Baseline in the Severity of Moderate to Severe Hot Flushes, Week 4, ITT Population
Time Frame: Baseline to Week 4
|
Patient self-reported outcome.
Severity of hot flush definitions: mild (1) - sensation of heat without perspiration, moderate (2) - sensation of heat with perspiration, able to continue activity, severe (3) - sensation of heat with perspiration, causing the subject to stop activity or awaken from sleep.
Minimum 0/no hot flushes, Maximum 3/all severe hot flushes.
Lower the score the greater the improvement in reducing hot flushes.
|
Baseline to Week 4
|
|
Mean Change From Baseline in the Severity of Moderate to Severe Hot Flushes, Week 12, ITT Population
Time Frame: Baseline to Week 12
|
Patient self-reported outcome.
Severity of hot flush definitions: mild (1) - sensation of heat without perspiration, moderate (2) - sensation of heat with perspiration, able to continue activity, severe (3) - sensation of heat with perspiration, causing the subject to stop activity or awaken from sleep.
Minimum 0/no hot flushes, Maximum 3/all severe hot flushes.
Lower the score the greater the improvement in reducing hot flushes.
|
Baseline to Week 12
|
|
Mean Change From Baseline in Total Urogenital Symptom Score, Week 4, ITT Population
Time Frame: Baseline to Week 4
|
Urogenital Symptom Severity scored none=0, mild=1, moderate=2, severe=3.
|
Baseline to Week 4
|
|
Change From Baseline in Total Urogenital Symptom Score, Week 8, ITT Population
Time Frame: Baseline to Week 8
|
Urogenital Symptom Severity scored none=0, mild=1, moderate=2, severe=3.
|
Baseline to Week 8
|
|
Change From Baseline in Total Urogenital Symptom Score, Week 12, ITT Population
Time Frame: Baseline to Week 12
|
Urogenital Symptom Severity scored none=0, mild=1, moderate=2, severe=3.
|
Baseline to Week 12
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Herman Ellman, MD, Warner Chilcott
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Hot Flashes
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptive Agents, Female
- Estradiol
- Estradiol 17 beta-cypionate
- Estradiol 3-benzoate
- Polyestradiol phosphate
- Estrogens
- Estrogens, Conjugated (USP)
Other Study ID Numbers
Other Study ID Numbers
- PR-03602.1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.